AU2014326257B2 - Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins - Google Patents

Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins Download PDF

Info

Publication number
AU2014326257B2
AU2014326257B2 AU2014326257A AU2014326257A AU2014326257B2 AU 2014326257 B2 AU2014326257 B2 AU 2014326257B2 AU 2014326257 A AU2014326257 A AU 2014326257A AU 2014326257 A AU2014326257 A AU 2014326257A AU 2014326257 B2 AU2014326257 B2 AU 2014326257B2
Authority
AU
Australia
Prior art keywords
fxa variant
seq
protein
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014326257A
Other languages
English (en)
Other versions
AU2014326257A1 (en
Inventor
Michael Anthony JANKOWSKI
Keith A. Johnson
Wendy Carol PIACENZA
Jason C. ROUSE
Michael Shamashkin
Penelope Jane SHARPE
Mary Beth Switzer
Stacey B. WESTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2014326257A1 publication Critical patent/AU2014326257A1/en
Application granted granted Critical
Publication of AU2014326257B2 publication Critical patent/AU2014326257B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
AU2014326257A 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins Ceased AU2014326257B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24
US61/881,834 2013-09-24
PCT/IB2014/064564 WO2015044836A1 (en) 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Publications (2)

Publication Number Publication Date
AU2014326257A1 AU2014326257A1 (en) 2016-03-10
AU2014326257B2 true AU2014326257B2 (en) 2017-08-10

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014326257A Ceased AU2014326257B2 (en) 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins

Country Status (19)

Country Link
US (3) US9757434B2 (enExample)
EP (1) EP3049434A1 (enExample)
JP (1) JP6429885B2 (enExample)
KR (1) KR101988705B1 (enExample)
CN (2) CN112195169A (enExample)
AR (1) AR097732A1 (enExample)
AU (1) AU2014326257B2 (enExample)
BR (1) BR112016005899A8 (enExample)
CA (1) CA2924981C (enExample)
HK (1) HK1218760A1 (enExample)
IL (2) IL244258A0 (enExample)
MX (1) MX373466B (enExample)
MY (1) MY173548A (enExample)
PE (1) PE20160877A1 (enExample)
RU (1) RU2648144C2 (enExample)
SA (1) SA516370751B1 (enExample)
SG (1) SG11201601221XA (enExample)
TW (1) TWI631134B (enExample)
WO (1) WO2015044836A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
CN112195169A (zh) 2013-09-24 2021-01-08 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
EP3926044B1 (en) 2016-06-17 2025-06-04 Alexion Pharmaceuticals, Inc. Preparation of factor xa derivatives
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition
EP4127158A2 (en) * 2020-04-02 2023-02-08 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175931A1 (en) * 2005-11-15 2009-07-09 Camire Rodney M Compositions and methods for modulating hemostasis
WO2013049804A1 (en) * 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
RU2396347C2 (ru) * 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
US8329871B2 (en) 2008-06-24 2012-12-11 Octapharma Ag Process of purifying coagulation factor VIII
CA2743496C (en) * 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
JP5833448B2 (ja) 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
EP2453910B1 (en) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
PT2591006T (pt) * 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
KR102049900B1 (ko) 2012-07-25 2019-11-28 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 인자 x 폴리펩티드 및 이의 용도
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
CN112195169A (zh) 2013-09-24 2021-01-08 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
US20160235824A1 (en) 2013-11-01 2016-08-18 The Children's Hospital Philadelphia Compositions and Methods for Increasing the Half-Life of Factor XA
CN105934250A (zh) 2014-01-24 2016-09-07 辉瑞公司 治疗脑内出血的组合物和方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175931A1 (en) * 2005-11-15 2009-07-09 Camire Rodney M Compositions and methods for modulating hemostasis
WO2013049804A1 (en) * 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUNCE, M.W. et al.: "Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro", BLOOD (2011), Vol.117 No.1 pg290-298 *
IVANCIU, L. et al.: "A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia", NATURE BIOTECHNOLOGY (2011), Vol. 29 No.11 pages 1028-1033 *
YAN-MEI SUN, et al.: "Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X", BLOOD (2005), Vol.106 No.12 pg 3811-3815 *

Also Published As

Publication number Publication date
TW201524996A (zh) 2015-07-01
HK1218760A1 (zh) 2017-03-10
JP2016535071A (ja) 2016-11-10
MX373466B (es) 2020-05-25
US20210106658A1 (en) 2021-04-15
BR112016005899A2 (pt) 2017-09-26
RU2016108608A (ru) 2017-10-26
EP3049434A1 (en) 2016-08-03
SA516370751B1 (ar) 2018-04-05
US20170333535A1 (en) 2017-11-23
CA2924981C (en) 2020-03-31
KR101988705B1 (ko) 2019-06-12
CN112195169A (zh) 2021-01-08
RU2648144C2 (ru) 2018-03-22
CN105579468A (zh) 2016-05-11
PE20160877A1 (es) 2016-09-11
AR097732A1 (es) 2016-04-13
US10660946B2 (en) 2020-05-26
IL279396A (en) 2021-01-31
US20150182604A1 (en) 2015-07-02
IL244258A0 (en) 2016-04-21
MY173548A (en) 2020-02-04
SG11201601221XA (en) 2016-04-28
JP6429885B2 (ja) 2018-11-28
BR112016005899A8 (pt) 2018-02-06
MX2016003871A (es) 2016-08-04
CA2924981A1 (en) 2015-04-02
TWI631134B (zh) 2018-08-01
US9757434B2 (en) 2017-09-12
AU2014326257A1 (en) 2016-03-10
WO2015044836A1 (en) 2015-04-02
KR20160044034A (ko) 2016-04-22

Similar Documents

Publication Publication Date Title
US20210106658A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP2108045B1 (en) Improved fix-mutant proteins for hemophilia b treatment
US20250230426A1 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
EP3467116A1 (en) Method for isolation of recombinantly produced proteins
EP2108046B1 (en) Fviii-independent fix-mutant proteins for hemophilia a treatment
AU2014202989B2 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
JP5722314B2 (ja) 高純度可溶性トロンボモジュリン及びその製造方法
HK40007078A (en) Method for isolation of recombinantly produced proteins
WO2017025566A1 (en) Improved recombinant factor vii
AU2016238889A1 (en) Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
HK1178048A (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
HK1151184A1 (zh) 重组纤维蛋白原
HK1151184B (en) Recombinant fibrinogen
KR20060104553A (ko) 항혈전 항체의 정제방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired